FDA begins review of Biogen's Eloctate; Ion Beam Applications to sell discovery unit; International team cites success for rotavirus vaccine in PhIII;

@FierceBiotech:  In case you missed it last week: Henri Termeer rediscovers the 'Genzyme feel' in world of biotech startups. Story | Follow @FierceBiotech

@JohnCFierce: Astellas chops OSI, Perseid ops in global R&D restructuring. Report | Follow @JohnCFierce

@RyanMFierce: AbbVie is forking over $70 million upfront in collab with Alvine for PhII drug against Celiac disease. Release | Follow @RyanMFierce

> Biogen Idec is on a roll. Shortly after winning an FDA approval for the MS drug Tecfidera, the FDA has now accepted the biotech's application for the long-acting hemophilia drug Eloctate for review. Story

> Belgium's Ion Beam Applications has struck a deal to sell its drug-discovery unit to a private equity group for $32.5 million. Story

> An international group of investigators from the U.S. and India joined forces in developing a new rotavirus vaccine that has proved effective in Phase III. Release

Medical Device News

@FierceMedDev: Study: FDA medical device inspections up 47% under Obama. More | Follow @FierceMedDev

@MarkHFierce: C.R. Bard has settled a DOJ case alleging kickbacks in exchange for use of its prostate cancer treatment. Release | Follow @MarkHFierce

 @DamianFierce: Invacare has cleared the first hurdle to getting past an FDA consent decree. Article | Follow @DamianFierce

> Boston Scientific accused of circumventing sale injunction in stent patent fight. Article

> HemCon, a struggling wound dressing device maker, is sold. Item

> Cizzle and Fujirebio team up for early-stage lung cancer Dx. DxExtra

Pharma News

@FiercePharma: Ranbaxy inks record-setting $500M manufacturing settlement with the feds: Report | Follow @FiercePharma

> France slaps Sanofi with $53M fine for 'disparaging' Plavix generics. More

> Merck execs' bogeymen: Animal-rights, disease activists, plus laid-off workers. Story

> AstraZeneca, Astellas among Optimer bidders, Bloomberg sources say. Report

Biotech Research News

 @EmilyMFierce: Compound developed by Salk Institute scientists protects against Alzheimer's-related disease behaviors. Report | Follow @EmilyMFierce

> New therapeutic target found for pancreatic cancer. News

> Gene silencing technique could pave way for new class of drugs. Story

> Hormone reverses heart failure symptoms in mice. Item

> Vaccine stops cocaine from reaching brain in monkeys. Article

Pharma Manufacturing News

> FDA says scale of compounding problem is unclear. Report

> Airborne transit mooted as source of remote drug contaminants. Article

> Ranbaxy pleads guilty in $500M case. Story

> USP opens training center in Ghana to raise standards. Item

> WHO clears way for Sanofi's antimalarial ingredient. More

And Finally… A new bird flu strain and a lethal coronavirus are raising fears of new outbreaks around the globe. Story

Suggested Articles

The biotech behind AstraZeneca and the University of Oxford’s late-stage pandemic vaccine has hired Margaret (Meg) Marshall, M.D., as its new CMO.

On the heels of a merger and $60 million private offering, Compass is looking to go public. It filed to raise up to $50 million in its Nasdaq IPO.

he results suggest V114 provides broader protection from pneumococcal bacteria than Prevnar 13 does, positioning Merck to muscle in on Pfizer’s turf.